Mufg Securities Americas Inc. Increases Stock Position in Johnson & Johnson $JNJ

Mufg Securities Americas Inc. increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 25.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,325 shares of the company’s stock after acquiring an additional 10,706 shares during the period. Johnson & Johnson makes up 0.7% of Mufg Securities Americas Inc.’s investment portfolio, making the stock its 20th largest holding. Mufg Securities Americas Inc.’s holdings in Johnson & Johnson were worth $8,145,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in JNJ. GFG Capital LLC purchased a new position in Johnson & Johnson during the second quarter valued at $35,000. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter worth about $47,000. 1248 Management LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter worth about $48,000. Harvest Fund Management Co. Ltd purchased a new stake in Johnson & Johnson during the 1st quarter valued at about $52,000. Finally, Pandora Wealth Inc. bought a new stake in Johnson & Johnson during the 1st quarter valued at about $65,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Scotiabank assumed coverage on shares of Johnson & Johnson in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 target price on the stock. The Goldman Sachs Group increased their target price on Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday, October 9th. Guggenheim upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Finally, Morgan Stanley set a $190.00 target price on Johnson & Johnson in a research report on Wednesday, October 15th. Four analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $201.05.

Johnson & Johnson Price Performance

NYSE JNJ opened at $203.88 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The business’s fifty day moving average is $188.25 and its 200 day moving average is $171.55. The company has a market capitalization of $491.21 billion, a PE ratio of 19.68, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $206.94.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.